Predict your next investment

Trellis Bioscience company logo
Corporation
HEALTHCARE | Biotechnology
trellisbio.com

See what CB Insights has to offer

Stage

Acquired

Total Raised

$41.64M

Investors Count

11

Deal Terms

4

Portfolio Exits

1

Investments

1

Trellis Bioscience Funding, Trellis Bioscience Valuation & Trellis Bioscience Revenue

11 Fundings

Trellis Bioscience's latest funding round was a Grant - II for $3.2M on January 13, 2020.

Trellis Bioscience's valuation in July 2009 was $52.68M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

1/13/2020

Grant - II

$3.2M

1

11/9/2011

Debt - II

$0.23M

1/6/2010

Grant

$0.48M

8/24/2009

Series C - II

$99M

0

7/6/2009

Series C

$99M

$52.68M

0

Date

1/13/2020

11/9/2011

1/6/2010

8/24/2009

7/6/2009

Round

Grant - II

Debt - II

Grant

Series C - II

Series C

Amount

$3.2M

$0.23M

$0.48M

$99M

$99M

Investors

Valuation

$52.68M

Revenue

Sources

1

0

0

Trellis Bioscience Deal Terms

4 Deal Terms

Trellis Bioscience's deal structure is available for 4 funding rounds, including their Series C from July 06, 2009.

Round

Series C

Series B

Series A - III

Series A

Funding Date

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

$99M

Post-Money Valuation

$99M

$99M

Amount Raised

$99M

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

Dividend Rate

$99M

$99M

Liquidation Preferences

$99M

$99M

Liquidation Price

Participation

$99M

Conversion Price

Anti Dilution

$99M

$99M

General Voting

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series C

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A - III

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Trellis Bioscience Investors

11 Investors

Trellis Bioscience has 11 investors. CARB-X invested in Trellis Bioscience's Grant - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/13/2020

1/13/2020

1
Grant - II

Public-Private Partnership

Massachusetts

4/12/2002

11/9/2011

8
Series C, Series B (2007), Series C - II (2009), Series A (2002), Series A - II (2004), Series A - III (2006), Debt (2009), Debt - II (2011)

Venture Capital

New York

11/9/2011

11/9/2011

1
Debt - II

Venture Capital

New York

00/00/0000

00/00/0000

Qualifying Therapeutic Discovery Project

Subscribe to see more

Government

DC

00/00/0000

00/00/0000

Morgenthaler Ventures

Subscribe to see more

Venture Capital

California

First funding

1/13/2020

4/12/2002

11/9/2011

00/00/0000

00/00/0000

Last Funding

1/13/2020

11/9/2011

11/9/2011

00/00/0000

00/00/0000

Investor

Qualifying Therapeutic Discovery Project

Morgenthaler Ventures

Rounds

1
Grant - II
8
Series C, Series B (2007), Series C - II (2009), Series A (2002), Series A - II (2004), Series A - III (2006), Debt (2009), Debt - II (2011)
1
Debt - II

Subscribe to see more

Subscribe to see more

Board Seats

Type

Public-Private Partnership

Venture Capital

Venture Capital

Government

Venture Capital

Location

Massachusetts

New York

New York

DC

California

Trellis Bioscience Investments

1 Investments

Trellis Bioscience has made 1 investments. Their latest investment was in Promedior as part of their Series A on February 2, 2008.

CBI Logo

Trellis Bioscience Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/6/2008

Series A

Promedior

$14M

Yes

Date

2/6/2008

Round

Series A

Company

Promedior

Amount

$14M

New?

Yes

Co-Investors

Sources

Trellis Bioscience Portfolio Exits

1 Portfolio Exit

Trellis Bioscience has 1 portfolio exit. Their latest portfolio exit was Promedior on November 15, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/15/2019

Acquired

$99M

4

Date

11/15/2019

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

4

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.